A

Amneal Pharmaceuticals Inc
F:2DT

Watchlist Manager
Amneal Pharmaceuticals Inc
F:2DT
Watchlist
Price: 10 EUR Market Closed
Market Cap: 3.1B EUR
Section:
 

Relative Value

The Relative Value of one 2DT stock under the Base Case scenario is hidden EUR. Compared to the current market price of 10 EUR, Amneal Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2DT Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.3
P/S
P/S
Price to Sales
1.3
vs History
7
vs Industry
71
Median 3Y
0.9
Median 5Y
0.8
Industry
2.6
Forward
1.2
More Details
625.2
P/E
P/E
Price to Earnings
625.2
vs History
9
vs Industry
Median 3Y
-21.2
Median 5Y
-4.8
Industry
21.6
Forward
14.6
More Details
11.3
P/OCF
P/OCF
Price to OCF
11.3
vs History
1
vs Industry
40
Median 3Y
8
Median 5Y
6.8
Industry
16.5
More Details
34.7
P/FCFE
P/FCFE
Price to FCFE
34.7
vs History
23
vs Industry
Median 3Y
-7.8
Median 5Y
-3.2
Industry
22.5
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
1.4
Median 5Y
3
Industry
2.3
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
22
vs Industry
55
Median 3Y
1.7
Median 5Y
1.9
Industry
2.9
Forward
2
More Details
5.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.7
vs History
34
vs Industry
41
Median 3Y
4.7
Median 5Y
4.9
Industry
5.5
More Details
10.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.1
vs History
30
vs Industry
36
Median 3Y
8.3
Median 5Y
8.9
Industry
13
Forward
8.8
More Details
16.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.9
vs History
63
vs Industry
30
Median 3Y
16.4
Median 5Y
19.2
Industry
16.6
Forward
10.7
More Details
18.6
EV/OCF
EV/OCF
Enterprise Value to OCF
18.6
vs History
28
vs Industry
26
Median 3Y
17.2
Median 5Y
16.5
Industry
15.8
More Details
25.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
25.8
vs History
23
vs Industry
21
Median 3Y
21.3
Median 5Y
21.2
Industry
19.1
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
1
vs Industry
42
Median 3Y
1.5
Median 5Y
1.3
Industry
1.9
More Details

Multiples Across Competitors

2DT Competitors Multiples
Amneal Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amneal Pharmaceuticals Inc
F:2DT
3.1B EUR 1.3 625.2 10.1 16.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.8 54.3 36.5 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
514.8B USD 5.6 20.5 16.7 21.7
CH
Roche Holding AG
SIX:ROG
255.4B CHF 4.1 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
211.2B GBP 4.9 30.1 108.4 158.7
CH
Novartis AG
SIX:NOVN
204.2B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
247.6B USD 3.8 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.5 9.6 11.1
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
149.9B USD 2.4 15.2 7.7 10.5
P/E Multiple
Earnings Growth PEG
US
A
Amneal Pharmaceuticals Inc
F:2DT
Average P/E: 90.8
625.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Amneal Pharmaceuticals Inc
F:2DT
Average EV/EBITDA: 399.9
10.1
12%
0.8
US
Eli Lilly and Co
NYSE:LLY
36.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
1%
7.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Amneal Pharmaceuticals Inc
F:2DT
Average EV/EBIT: 1 711.8
16.9
29%
0.6
US
Eli Lilly and Co
NYSE:LLY
39.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
8%
1.3

See Also

Summary
2DT intrinsic value, competitors valuation, and company profile.
DCF Valuation
2DT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
2DT stock valuation using valuation multiples.
Wall Street Estimates
2DT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
2DT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.